CD19 and lymphoma: found that mice receiving vancomycin in combination with CD19-directed CAR-T cell therapy showed increased tumor response and tumor-associated antigens (TAAs) cross-presentation compared with those of mice receiving CD19 CAR-T cell therapy alone in lymphoma murine model (23).